Updates

September 21, 2020September 21, 2020
Rigosertib Combo Fails to Prolong Survival in Higher-risk Myelodysplastic Syndromes

When given alongside best supportive care, rigosertib failed to prolong the survival of patients with higher-risk myelodysplastic syndromes (HR-MDS), a group of blood cancers ... Read more
September 17, 2020September 17, 2020
FDA Grants Rare Pediatric Disease Status to AML Therapy OXi-4503

The U.S. Food and Drug Administration (FDA) has granted its Rare Pediatric Disease designation to Mateon Therapeutics’ OXi-4503 (combretastatin A1-diphosphate, CA1P) for the treatment ... Read more
September 14, 2020September 14, 2020
French Authorities Advance Phase 3 Trial Testing Sellas’ GPS Cancer Vaccine

French regulatory authorities have approved an investigational medicinal product dossier (IMPD) from Sellas Life Sciences, granting permission to advance in France a Phase 3 ... Read more
September 10, 2020September 9, 2020
LLS Highlights Its Support Programs During Blood Cancer Awareness Month

Throughout September for Blood Cancer Awareness Month, the Leukemia & Lymphoma Society (LLS) is asking the public to join its commitment to research, education, advocacy, and ... Read more
September 3, 2020September 3, 2020
FDA Approves Oral Chemotherapy Onureg for Newly Diagnosed AML Patients in Remission

The U.S. Food and Drug Administration has approved Onureg, an oral formulation of the chemotherapy azacitidine, as a maintenance treatment for adults with newly ... Read more

Subscribe to our mailing list

Get regular updates delivered to your email box.

Thanks! Please check your email for a confirmation email.

Updates

Rigosertib Combo Fails to Prolong Survival in Higher-risk Myelodysplastic Syndromes

FDA Grants Rare Pediatric Disease Status to AML Therapy OXi-4503

French Authorities Advance Phase 3 Trial Testing Sellas’ GPS Cancer Vaccine

LLS Highlights Its Support Programs During Blood Cancer Awareness Month

FDA Approves Oral Chemotherapy Onureg for Newly Diagnosed AML Patients in Remission

Same But Different Photo Contest Celebrates People With Rare Diseases

Idhifa Combo Fails to Prolong Survival in Older Patients in Phase 3 Trial

Venclexta Plus Vidaza Increases AML Survival, Study Shows

Xperiome Platform Aims to Streamline Searches for Rare Diseases, Gain Patient Input

Phase 1 Trial for Potential Oral Therapy CB-5339 for Myeloid Cancers Doses First Patient

EveryLife Foundation Launches Scholarship Fund for Rare Disease Community in US

Subscribe to our mailing list

New Streaming Channel Showcases Rare Disease Films

Biosight’s Less Toxic Chemo BST-236 Wins FDA Fast Track Status for AML

Rare Disease Communities Invited to Submit Works to 2020 Rare Artist Contest

Trial of CPI-613 in Older AML Patients Moves Closer to 1st Interim Analysis

Blood Cancer Groups Unite to Award $6.75M to ‘Propel Discoveries’

New Molecule Shows Promise as Potential Cancer Vaccine for AML

First Patient Dosed in Phase 1 Trial Testing Small Molecule Treatment CA-4948 for AML

Helsinn, Mei Pharma Stop Phase 3 Trial of Pracinostat-Vidaza Combo for AML

FDA Allows Human Trials of Aptose’s CG-806 Oral Compound for AML

Venclexta Combo Continues to Help Untreated AML Patients in Phase 3 Trial

Daurismo Combo Approved in Europe for Select Adults With AML

FDA’s New ‘Project Patient Voice’ to Share Symptoms Data From Cancer Trials

Cost of Cancer Treatment in US Could Rise by 34% by 2030

Genetic Testing Often Worth the Wait for More Tailored Treatments, Study Says

FDA Approves Mylotarg as First-Line AML Treatment for Children

Moleculin Seeks Two More Test Sites in European Annamycin Trial

Protocol First Wins Funding for Beat AML Clinical Trial

Coalition Will Address Racial Disparities in Rare Disease Communities

Intellia Looking to Bring Its Potential T-cell Therapy for AML into Trials

MacroGenics Plans Registration Study of Flotetuzumab for Hard-to-treat AML Patients

FDA OKs Phase 1 Trial of Antibody, IO-202, to Treat Advanced AML and CMML

COVID-19 Delaying Rare Disease and Gene Therapy Trials, Pharma Execs Say

Pin It on Pinterest